Oral small molecule GLP-1 receptor agonist
Alenig po
ALENIG_PO
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -7.04 (-18.88 to 5.83) | 0.78 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.81 (-16.30 to -1.69) | 0.80 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.06 (-15.63 to -1.27) | 0.75 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.57 (0.13 to 2.88) | 0.75 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.00 (0.59 to 8.48) | 0.53 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.59 (2.43 to 9.16) | 0.36 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.20 (2.68 to 31.34) | 0.32 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.58 (0.70 to 3.68) | 0.59 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.57 (1.06 to 6.88) | 0.40 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.01 (0.79 to 37.90) | 0.34 |